1 / 5

In 2023, automation may encourage more innovation and future developments

According to a recent FDA count, there are currently 27 different cell and gene therapies authorised in the United States. During the next ten years, that number is anticipated to soar due to the hundreds of corporations directing their prospects toward the clinic.<br>https://biointel360.com<br><br>#AsiaPacificGeneEditingMarketResearch #CellTherapyMarketSize #EuropePrecisionMedicineMarketReport #AsiaPacificPrecisionMedicineMarketResearch #BiotechnologyMarketResearchReport<br>#GlobalBiotechnologyResearchReport

Bio8
Download Presentation

In 2023, automation may encourage more innovation and future developments

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. In 2023, automation may encourage more innovation and future developments in the cell and gene therapy sector According to a recent FDA count, there are currently 27 different cell and gene therapies authorised in the United States. During the next ten years, that number is anticipated to soar due to the hundreds of corporations directing their prospects toward the clinic. To support the production of the upcoming wave of products at scale, current cell, and gene manufacturing must quickly catch up. Automation, robots, and point-of-care manufacturing techniques bundled in compact yet effective production settings may contain the solution.

  2. BioIntel360

  3. Read more: Allogeneic CAR T cell therapy to enter the neuro-oncology sector Current CGT manufacture requires a lot of manual work because it is delicate, expensive, and difficult to scale. That workflow is already partially automated, but it has the potential to be automated even more. Although competent and trained scientists will always be needed for production, the aspects of the manufacturing process that are most vulnerable to human error need to be automated.

  4. Regarding automation already in use: Cytiva has partnered with robotics technology company Multiply Labs to design a robotic system that would automate the manual processes involved in producing cell therapy to reduce the risk of human error and speed up production on an "industrial scale." The Multiply Labs robotic cluster, which consists of a robotic arm surrounded by manufacturing modules and slides and pivots to move materials through production, will be the focus of the Cytiva-Multiply trial.

  5. Contact Us info@biointel360.com + 1 (813) 694-7124 http://biointel360.com/

More Related